Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LORI H TRAVIS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1093794885
CMS profile
276843
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$57,757.69

248 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LORI H TRAVIS

NPI 1093794885 · CMS profile ID 276843

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093794885?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LORI H TRAVIS, NPI 1093794885, CMS profile ID 276843. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093794885?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LORI H TRAVIS, NPI 1093794885, CMS profile ID 276843. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093794885?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LORI H TRAVIS, NPI 1093794885, CMS profile ID 276843, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1093794885?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

248 matching records · $57,757.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 248 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 248.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $28.7508/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783698949 CMS
EMD Serono, Inc. $9.2508/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849203325 CMS
Novartis Pharmaceuticals Corporation $12.8208/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813321397 CMS
GENZYME CORPORATION $956.0008/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843529191 CMS
AbbVie Inc. $5.1908/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796170043 CMS
Novartis Pharmaceuticals Corporation $5.5608/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813321389 CMS
Janssen Pharmaceuticals, Inc $0.8708/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734143 CMS
Janssen Pharmaceuticals, Inc $8.9808/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734155 CMS
AbbVie Inc. $12.1307/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796170041 CMS
Genentech USA, Inc. $19.2707/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835942343 CMS
Novartis Pharmaceuticals Corporation $3.7107/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813321393 CMS
AbbVie Inc. $5.5807/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796170039 CMS
Biogen, Inc. $20.6607/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827845021 CMS
Alexion Pharmaceuticals, Inc. $26.7107/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783120517 CMS
AbbVie Inc. $6.7807/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796170037 CMS
Biogen, Inc. $14.8307/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827845023 CMS
Celgene Corporation $19.5307/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783698945 CMS
Novartis Pharmaceuticals Corporation $9.0307/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813321377 CMS
Janssen Pharmaceuticals, Inc $0.9707/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734109 CMS
Janssen Pharmaceuticals, Inc $14.5207/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734127 CMS
Biogen, Inc. $359.0007/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827844985 CMS
Biogen, Inc. $18.2007/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827844997 CMS
Mallinckrodt Hospital Products Inc. $3,430.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845383351 CMS
BANNER LIFE SCIENCES, LLC $59.0806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843738731 CMS
Janssen Pharmaceuticals, Inc $8.2206/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734379 CMS
Janssen Pharmaceuticals, Inc $2.8906/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734392 CMS
Mallinckrodt Hospital Products Inc. $112.5006/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845383349 CMS
Biogen, Inc. $23.6006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827845001 CMS
Janssen Pharmaceuticals, Inc $8.1606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734085 CMS
Janssen Pharmaceuticals, Inc $1.7606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734100 CMS
Horizon Therapeutics plc $14.7506/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797220323 CMS
Novartis Pharmaceuticals Corporation $16.9806/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813321385 CMS
AbbVie Inc. $3.6806/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796170035 CMS
Biohaven Pharmaceuticals, Inc. $17.6906/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852644221 CMS
Teva Pharmaceuticals USA, Inc. $16.0906/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839665825 CMS
GENZYME CORPORATION $2,825.0006/18/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843529135 CMS
AbbVie Inc. $15.4706/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796170033 CMS
EMD Serono, Inc. $7.4506/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849195051 CMS
Novartis Pharmaceuticals Corporation $3.9006/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813321381 CMS
Celgene Corporation $20.6206/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783698943 CMS
Janssen Pharmaceuticals, Inc $9.3506/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734059 CMS
Janssen Pharmaceuticals, Inc $0.4506/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787734071 CMS
Novartis Pharmaceuticals Corporation $7.1706/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813321373 CMS
Celgene Corporation $21.4406/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783698941 CMS
Biogen, Inc. $23.7706/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827845019 CMS
Novartis Pharmaceuticals Corporation $6.3006/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813321365 CMS
EMD Serono, Inc. $400.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849149995 CMS
GENZYME CORPORATION $14.1606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843529281 CMS
Novartis Pharmaceuticals Corporation $2,128.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813321273 CMS
Biogen, Inc. $269.0006/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827844983 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $157,011.41 174
PY2020 $49,159.95 100
PY2021 $57,757.69 248
PY2022 $51,454.40 292
PY2023 $18,043.97 245
PY2024 $40,882.71 279
PY2025 $31,203.58 255

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $82,186.65 12
PY2024 Principal investigator $151,827.45 16
PY2023 Principal investigator $180,293.02 64
PY2022 Principal investigator $557,973.54 22
PY2021 Principal investigator $112,269.30 11
PY2020 Recipient $1,009.93 2
PY2020 Principal investigator $8,594.80 6
PY2019 Principal investigator $750.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $4,038.60 11/17/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148780
Principal investigator 1 GENZYME CORPORATION $4,038.60 09/29/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148776
Principal investigator 1 GENZYME CORPORATION $5,098.00 08/11/2025 Non-covered Recipient Entity
Perseverance Research Center
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226148772
Principal investigator 1 GENZYME CORPORATION $5,156.08 08/04/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148762
Principal investigator 1 GENZYME CORPORATION $7,175.38 08/04/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148765
Principal investigator 1 GENZYME CORPORATION $3,500.00 08/04/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148768
Principal investigator 1 GENZYME CORPORATION $6,057.90 07/02/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148871
Principal investigator 1 GENZYME CORPORATION $12,610.20 05/19/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148844
Principal investigator 1 GENZYME CORPORATION $1,650.00 04/21/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148821
Principal investigator 1 GENZYME CORPORATION $23,000.00 03/17/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148796
Principal investigator 1 GENZYME CORPORATION $6,500.00 02/18/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148790
Principal investigator 1 GENZYME CORPORATION $3,361.89 01/27/2025 Non-covered Recipient Entity
Perseverance Research Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148801